

CRL follow up

Company	Product	CRL:Date	Resubmission	class	estimated date of FDA	Stock Value 2/5	low 52w	high 42w	cash	yearly cash burn	avarage target
Adma Biologics	Bivigam	19/12/2018	7/01/2019	2	?7/08/2019	4.51	2.08	6.96			12.5
Immunomedics	Sacituzumab	17/01/2019	?6/2019	2	?12/2019	15	11.5	27.33			25.4
Evoke Pharma	Gimoti	2/04/2019	?	?	?	0,71	0.7	3.4			8
Nabriva		30/04/2019	?	?	?	2.2	1.12	6.05			8.5
Heron Therapeutics	HTX-011	1/05/2019	?	?	?	17,54	16,2	42,9			45.5

Note: received 2/4 approval for another product